

TECNOLOGIE WITNESS E CRIOCONSERVAZIONE

Roberta Maggiulli

Centro GENERA – Medicina della Riproduzione Roma, Marostica, Napoli, Umbertide



Optimizing
Human Gamete
and Embryo Freezing

13 giugno 2014



HFEA guidance

Human Fertilisation and Embryology (HFE) Act 1990 (as amended)

- 2 Other terms
- (1) "traceability" means the ability-
 - (a) to identify and locate gametes and embryos during any step from procurement to use for human application or disposal,
 - (b) identify the donor and recipient of particular gametes or embryos,
 - (c) to identify any person who has carried out any activity in relation to particular gametes or embryos, and
 - (d) to identify and locate all relevant data relating to products and materials coming into contact with particular gametes or embryos and which can affect their quality or safety.



HFEA guidance

Witnessing clinical and laboratory procedures



Mandatory requirements

Licence conditions

T71 Centres must have in place robust and effective processes to ensure that no mismatches of gametes or embryos or identification errors occur. Centres must double check the identification of samples and the patients or donors to whom they relate at all critical points of the clinical and laboratory process. These checks must be completed and recorded at the time the relevant clinical or laboratory process/procedure takes place. A record must be kept in each patient's/donor's medical record.



HFEA guidance

Witnessing clinical and laboratory procedures

- Witnessing protocols should ensure that every sample of gametes or embryos can be <u>identified at all</u> stages of the laboratory and treatment process to prevent any mismatches of gametes or embryos.
- 18.2 Centres are responsible for ensuring that witnessing protocols are relevant to their local systems and conditions, based on HFEA model protocols. Where appropriate, clinics may adapt HFEA model protocols to take into account their local systems.

See also:

- Relevant HFEA model protocols at: www.hfea.gov.uk/docs/witnessing-protocols.pdf
- 18.3 Electronic systems such as barcoding and radio frequency identification (RFID) for assisted conception are appropriate, subject to a risk assessment as set out at 18.34–18.43.



ELECTRONIC WITNESSING: OUR EXPERIENCE

- Significant increase in the number of IVF cycles performed at our centre
- Need to improve our lab efficiency

Double manual witnessing is time consuming and distracting
Concept of "Involuntary automaticity"→ the second witness may see what he "expected to see"

	RI Witness™	Barcoding systems such as Matcher™ and Human double-witnessing
Sample Checking / Forcing Function	The system scans and detects all labware automatically where procedures are performed. Therefore, users cannot skip a check or perform a procedure without being checked.	The labware must be presented by the user for identification (either to a barcode reader, or a human witness). The safety of the lab therefore relies on people remembering to perform the checks.
Prevention of mistakes	If incompatible labware is brought into the working area then the user is immediately alerted visually and audibly before any work can be carried out. A potential mistake is therefore avoided.	For a potential mistake to be avoided, the user must remember to initiate a check prior to commencing work. When using multiple dishes and tubes, great care must be taken to ensure that all the labware has been correctly checked.



OUR EXPERIENCE: ELECTRONIC WITNESSING





OBSERVATIONAL STUDY - OBSERVED OUTCOMES

Timing required for an ex-novo installation of an electronic witnessing system (RI Witness[™]) into a busy IVF clinic:

to integrate and install the system in the working area



flow-chart

- Patient Satisfaction
- for the training of all the clinical embryologists





INTEGRATION OF THE SYSTEM



- Work Area Readers
- Controlling Software 4 working days
- PC Ad Monitor
- Barcode Reader
- Training of Laboratory Staff ————> 7 working days





VALIDATION PERIOD - SEPTEMBER 2012



Adjustment of the system workflow according to our laboratory's existing protocols


Reduction of the system users errors to less than 1%

Double manual witnessing simultaneously performed




"True mismatches"= mismatches derived from a simultaneous presence of two different patient samples in the working area

 "Secondary mismatches" = mismatches derived from acceptable common errors (i.e. preallocated tags within the frequency range of the reader, but outside of the workstation)






CONFIGURATION OF THE WORKING FLOW CHART




RESULTS





	Validation period	Post-validation period
Patients (N)	302	852
Witnessing steps (N)	2099	5921
Mismatch rate (%)	0.80% (17/2099)	0.66% (39/5921)
"True mismatch" rate (%)	0.09% (2/2099)	0.10% (6/5921)
"Secondary mismatch" rate (%)	0.71% (15/2099)	0.56% (33/5921)

0.1% mismatch/step x 7 steps/cycle = ~0.7% mismatch/cycle x 0.25 pregnancy/cycle= ~0.17% mismatch/pregnancy



Center for Reproductive Medicine presents:

Implementing An Electronic Witnessing System Into A Busy IVF Clinic



ELECTRONIC WITNESSING: CRYO ELEMENTS






• A secure system providing exit and entry point management between the Lab & cryopreservation using Brady® barcode labels.





ELECTRONIC WITNESSING: CRYO ELEMENTS






ELECTRONIC WITNESSING: CRYO ELEMENTS





ELECTRONIC WITNESSING: WEAKNESS








To provide a proof of concept for a direct oocyte/embryo labeling system












In vitro development of embryos microinjected with different types of polysilicon barcodes into their perivitelline space.





HUMAN OOCYTES






Table V Morphokinetic parameters of control and tagged embryos developed up to full blastocyst stage.

Parameter analyzed	Time (h ± SEM (n))		
	Control	Tagged	
Disappearance of pronuclei time-point	9.1 ± 0.6 (16)	8.2 ± 0.7 (19)	
1 st cytokinesis duration	0.45 ± 0.03 (19)	0.47 ± 0.05 (21)	
2-Cell stage time-point	13.9 ± 1.8 (19)	$11.9 \pm 0.8 (21)$	
Reappearance of nuclei after first cleavage time-point	$15.2 \pm 0.9 (10)$	16.1 ± 1.5 (13)	
Reappearance of nuclei after first cleavage duration	$3.0 \pm 0.4 (10)$	3.3 ± 0.5 (13)	
3-Cell stage time-point ^a	$26.5 \pm 2.8 (17)$	$24.6 \pm 1.3 (18)$	
2-Cell stage duration ^a	$12.6 \pm 0.6 (17)$	$12.7 \pm 0.7 (18)$	
4-Cell stage time-point	$27.4 \pm 2.4 (19)$	26.2 ± 1.2 (21)	
3-Cell stage duration ^a	1.0 ± 0.2 (17)	1.3 ± 0.3 (18)	
5-Cell stage time-point	$39.2 \pm 2.6 (19)$	$41.8 \pm 2.2 (21)$	
Compaction time-point	77.2 ± 1.9 (19)	75.2 ± 1.4 (21)	
Morula time-point	$85.4 \pm 2.0 (19)$	84.0 \pm 1.7 (21)	
Blastocyst time-point	94.8 \pm 2.0 (19)	92.0 ± 1.9 (21)	
Full Blastocyst time-point	$104.1 \pm 2.4 (19)$	101.2 ± 2.3 (21)	

SEM, standard error of the mean. No significant differences were detected for any parameter analyzed between control and tagged embryos (P > 0.05; Mann–Whitney and Student's t-test).

^aData for two control and three tagged embryos that divided directly from 1 to 3 cells are missing.




Table IV Cell counts in Day 6 blastocysts after differential staining.

Group	No. of blastocysts	Mean number of cells/blastocyst ± SEM			Mean of ICM/TCN ratios ± SEM
		TCN	ICM	TE	
Control	24	100.9 ± 11.2	22.3 ± 1.9	78.5 ± 9.4	0.24 <u>+</u> 0.01
Tagged	25	111.9 ± 13.6	24.7 ± 2.5	87.2 <u>+</u> 11.3	0.23 ± 0.01

No significant differences were detected for any of the parameters analyzed between control and tagged blastocysts (P > 0.05; Mann—Whitney and Student's t-test). SEM, standard error of the mean; TCN, total cell number; ICM, inner cell mass; TE, trophectoderm.



ELECTRONIC WITNESSING: PATIENT SATISFACTION


Does the introduction of an electronic witnessing system in the IVF lab hold the potential to reduce patients anxiety about mismatching errors and to enhance couple satisfaction?







A questionnaire consisting of 8 items was developed on the basis of patients forum and literature analysis on the topic.



Sociodemographic variables:


- Age
- Gender
- Education
- Previous IVF treatments



ELECTRONIC WITNESSING: PATIENT SATISFACTION












Concerned about IVF "mixup"?




ON



ELECTRONIC WITNESSING: PATIENT SATISFACTION

A Contester neeth oculti d/F v/vit by-EgyV/?






9g.en.e.r.a.


ELECTRONIC WITNESSING: PATIENT SATISFACTION



Traceability



Patients reassurance



Multiple logistic regression analysis did not revealed any influence of socio-demographic variables on patient's attitudes toward IVF electronic witness system.

BENEFITS



- Easy to implement
- Safeguards the reliability of the entire IVF process
- Traceability of each step performed
- Reduction of staff workload and distractions
- Patients reassurance



CLINICAL DIRECTOR: Filippo Maria Ubaldi

Rome

Elena Baroni Silvia Colamaria Maddalena Giuliani Susanna Ferrero Fabio Sapienza

CIPA

Michele Ermini Beatrice Ermini



Mauro Schimberni Annalise Giallonardo Giovanna Vettraino

Marostica

Antonio Ciconte Silvia Venanzi Laura Buffo Antonio Gugole Angelo Moratello

Umbertide

Antonio Angelini Emanuela Migliorati Fabrizio Fiorini

LABORATORY DIRECTOR: Laura Rienzi

Rome

Roberta Maggiulli Laura Albricci Antonio Capalbo Federica Sanges Catello Scarica Elena levoli Lisa Dovere Marta Stoppa Danilo Cimadomo Giovanna Orlando Emiliano Scepi Erminia Alviggi

Stefania Romano

Marostica

Benedetta Iussig Ludovica Dusi Sara Bertelle

Umbertide

Nicoletta Barnocchi Letizia Papini

